Table 3.
Effect of NRBC on primary and secondary clinical outcomes
| Model (All subjects = 354) |
90-day mortality (n = 122, 34.46%) |
28-day mortality (n = 89, 25.14%) |
In-ICU mortality (n = 70, 19.77%) |
|---|---|---|---|
| Crude model OR (95% CI) | 1.412 (1.154–1.727) | 1.349 (1.088–1.673) | 1.586 (1.258–2.000) |
| P-value | < 0.001 | 0.006 | < 0.001 |
| Adjusted Model1 OR (95% CI) | 1.438 (1.165–1.776) | 1.391 (1.108–1.746) | 1.627 (1.284–2.062) |
| P-value | 0.001 | 0.004 | < 0.001 |
| Adjusted Model2 OR (95% CI) | 1.436 (1.162–1.776) | 1.374 (1.093–1.726) | 1.609 (1.269–2.041) |
| P-value | 0.001 | 0.006 | < 0.001 |
| Adjusted Model3 OR (95% CI) | 1.282 (1.020–1.611) | 1.162 (0.903–1.494) | 1.444 (1.084–1.923) |
| P-value | 0.033 | 0.242 | 0.012 |
Note: Crude model: unadjusted for confounding factors; Model1: adjusted for sex and age; Model2: adjusted for sex, race, and age; Model3: adjusted for age, CHF, Renal disease, Vasopressin, Norepinephrine, SOFA, SAPSII, OASIS, LODS, APSIII, and MAP. Abbreviations: APS III, Acute Physiology Score III; CHF, Congestive Heart Failure; LODS, Logistic Organ Dysfunction System; MAP, Mean Arterial Pressure; NRBC, Nucleated Red blood Cells; OASIS, Oxford Acute Severity of Illness Score; SAPS II, Simplified Acute Physiology Score II; SOFA, Sequential Organ Failure Assessment